Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

BACKGROUND: The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabrese, Joseph R., Jin, Na, Johnson, Brian, Such, Pedro, Baker, Ross A., Madera, Jessica, Hertel, Peter, Ottinger, Jocelyn, Amatniek, Joan, Kawasaki, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162003/
https://www.ncbi.nlm.nih.gov/pubmed/29886522
http://dx.doi.org/10.1186/s40345-018-0122-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162003/
https://www.ncbi.nlm.nih.gov/pubmed/29886522
http://dx.doi.org/10.1186/s40345-018-0122-z

Ejemplares similares